JPMorgan Chase & Co. Grows Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

JPMorgan Chase & Co. grew its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) by 6.1% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,176,191 shares of the company’s stock after purchasing an additional 67,464 shares during the period. JPMorgan Chase & Co.’s holdings in Recursion Pharmaceuticals were worth $7,751,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Charles Schwab Investment Management Inc. lifted its holdings in Recursion Pharmaceuticals by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock worth $12,789,000 after buying an additional 288,926 shares in the last quarter. FMR LLC increased its position in shares of Recursion Pharmaceuticals by 2.1% during the third quarter. FMR LLC now owns 8,363,530 shares of the company’s stock worth $55,116,000 after acquiring an additional 170,810 shares during the last quarter. State Street Corp lifted its stake in shares of Recursion Pharmaceuticals by 47.1% in the third quarter. State Street Corp now owns 12,870,272 shares of the company’s stock worth $84,815,000 after acquiring an additional 4,120,685 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Recursion Pharmaceuticals by 13.7% in the third quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock valued at $35,803,000 after purchasing an additional 656,003 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in Recursion Pharmaceuticals during the 2nd quarter valued at approximately $5,769,000. 89.06% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have recently commented on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $8.75.

Recursion Pharmaceuticals Stock Performance

RXRX stock opened at $6.32 on Wednesday. The firm has a market cap of $2.47 billion, a P/E ratio of -4.13 and a beta of 0.85. The stock’s 50 day simple moving average is $6.93 and its 200 day simple moving average is $6.97. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 12-month low of $5.60 and a 12-month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company’s quarterly revenue was up 147.6% on a year-over-year basis. During the same period last year, the firm posted ($0.43) earnings per share. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.

Insider Transactions at Recursion Pharmaceuticals

In related news, CFO Michael Secora sold 15,000 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at $11,487,173.46. This trade represents a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction dated Tuesday, October 29th. The shares were sold at an average price of $6.72, for a total transaction of $76,923.84. Following the transaction, the director now directly owns 7,077,560 shares of the company’s stock, valued at $47,561,203.20. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 43,894 shares of company stock worth $317,139. 15.75% of the stock is currently owned by company insiders.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.